Drug Type Synthetic peptide vaccine, Therapeutic vaccine |
Synonyms Alrefimotide acetate/riletamotide acetate/tapderimotide acetate, UV1 synthetic peptide vaccine, alrefimotide/tapderimotide/riletamotide + [2] |
Target |
Mechanism Telomerase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU), Fast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant Pleural Mesothelioma | Phase 2 | AU | 04 May 2020 | |
Malignant Pleural Mesothelioma | Phase 2 | DK | 04 May 2020 | |
Malignant Pleural Mesothelioma | Phase 2 | ES | 04 May 2020 | |
Malignant Pleural Mesothelioma | Phase 2 | DK | 04 May 2020 | |
Malignant Pleural Mesothelioma | Phase 2 | ES | 04 May 2020 | |
Malignant Pleural Mesothelioma | Phase 2 | SE | 04 May 2020 | |
Melanoma | Phase 2 | NO | 02 Feb 2015 | |
Castration-sensitive prostate cancer | Phase 2 | NO | 15 Apr 2013 | |
Prostatic Cancer | Phase 2 | NO | 15 Apr 2013 | |
Non-Small Cell Lung Cancer | Phase 2 | NO | 08 Apr 2013 |
Phase 1 | Metastatic melanoma First line | 10 | (cdynajdzgl) = csyaxaqsjg cprfxjpjoe (hqzjtmzdiq ) View more | Positive | 12 Aug 2021 | ||
(cohort 1) | (gwzieqaodn) = vpvqvcluda maqmhmtixb (saeunqkjnr ) | ||||||
Phase 1 | 18 | (okdmvlodmy) = lfskrawrpv srpjozllnb (ozzznpjahb ) View more | - | 01 Jan 2020 | |||
NCT02275416 (Pubmed) Manual | Phase 1/2 | 12 | (qyvtlfuoza) = gkpmkbztxa qhejopwarb (vrnfjschcd ) View more | Positive | 11 Sep 2022 | ||
Phase 1/2 | 12 | (ynctaemxqh) = diarrhea, injection site reaction, pruritus, rash, nausea and fatigue eabgggujbi (pfkmoydhqn ) | Positive | 11 May 2021 | |||
Phase 1/2 | 22 | (kxidgloktz) = qfpkmyldtr yaiibxqrno (djebuoupws ) View more | - | 30 Jan 2023 | |||
Phase 1 | 30 | UV1+pembrolizumab | (ghjejzsjwk) = fatigue (8%), injection site reaction (5%), diarrhea (4%) and pyrexia (3%) mrnvcpewvc (ufknbnjvxo ) View more | Positive | 28 May 2021 | ||
Phase 2 | Mesothelioma, Malignant Second line | 118 | (gpdlqxkfxm) = figfinzupb lipjkmmcpy (frsnwumvmb, 2.9 - 9.8) Not Met View more | Positive | 21 Oct 2023 | ||
(gpdlqxkfxm) = rfrizowhpk lipjkmmcpy (frsnwumvmb, 0.64 - 1.59) Not Met View more |